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ABSTRACT
Hypoxia is due to imbalance in oxygen supply and oxygen demand compromising biological 
functions of cells. Since tumor hypoxia results in angiogenesis, apoptosis, metastasis, 
tumor aggressiveness and treatment failure, in vivo measurement is required. Nuclear 
imaging can provide information about tissue oxygen levels. 2-nitroimidazole containing 
compounds selectively accumulate in hypoxic cells. They have been radiolabeled with 18F, 
123/124I, and 99mTc and used in clinical trial stages using PET and SPECT techniques. 62/64Cu-
ATSM is a non-imidazole imaging agent, which is trapped in hypoxic cells. There is a 
great interest in the development of 99mTc-labeled 2-nitroimidazole compounds. Though 
novel compounds based on molecular mechanisms of hypoxia would be developed in 
future.
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•	 Tumor hypoxia results in angiogenesis, apoptosis, metastasis, tumor aggressiveness, and treatment failure.
•	 Nuclear imaging can provide information about tissue oxygen levels. 
•	 2-nitroimidazole compounds selectively accumulate in hypoxic cells.
•	 At present a few PET radiopharmaceuticals as hypoxia imaging agents are in clinical trial stages.
Introduction 
Hypoxia	 is	 defined	 as	 a	 condition	 in	which	 the	 oxygen	
level in tissues is below physiologic levels, which is 
due to imbalance in oxygen supply and oxygen demand 
compromising biological functions of cells. Hypoxia is 
categorized as chronic (diffusion limited hypoxia) and 
acute (caused by blood clots or tumor cell aggregation). 
Oxygen diffuses through capillaries into intracellular 
environment.	 Insufficient	 supply	 of	 oxygen	 changes	
intracellular metabolism, which results in several 
biological consequences depending on levels of hypoxia 
(Span and Bussink, 2015). 
Solid tumors frequently face hypoxia because of 
abnormal changes in structure and function of the tumor 
vasculature together with altered diffusion conditions 
inside the tumor. In response to hypoxia, cells try to adapt 
themselves by up-regulating the production of numerous 
proteins. Many of the adaptations are by means of 
transcription factor Hypoxia inducible factor 1 (HIF-1). 
HIF-1 induces the target genes and leads hypoxic cells to 
up-regulate more than 100 proteins to overcome hypoxia 
and survive. It is well documented that tumor hypoxia 
results in angiogenesis, apoptosis, metastasis, tumor 
aggressiveness, and treatment failure (chemo-resistance 
and radio-resistance) (Mees et al., 2009; Sun et al., 2011; 
Span and Bussink, 2015). 
Hypoxia measurements 
Since tumor hypoxia has a poor prognosis, in vivo 
measurement of tumor hypoxia is required for assessing 
the aggressiveness of tumor and predicting the outcome 
of therapy. A variety of invasive and non-invasive 
techniques have been introduced for direct or indirect 
tumor hypoxia measurement. The gold standard of direct 
measurement is polarographic needle, which is inserted 
directly into a tumor. There are some drawbacks applying 
such technique including being invasive, requiring CT 
or ultrasound-guided placement as well as accessible 
tumors. Although it has been used in human tumors and 
animal models, it  has never been approved to be used in 
clinical setting (Zhang et al., 2000; Le and Courter, 2008; 
Krohn et al., 2008; Span and Bussink, 2015). 
Other methods such as phosphorescence imaging, 
blood oxygen level dependent, 19F magnetic resonance 
imaging, and electron paramagnetic resonance imaging 
have also been used for direct measurement of hypoxia 
(Le and Courter, 2008; Mason et al., 2010). 
Indirect measurements utilize molecular reporters 
of oxygen, which form stable adducts with intracellular 
macromolecules. The adducts fail to be formed at 
higher oxygen level (Le and Courter, 2008; Sun et al., 
2011). 2-nitroimidazoles such as misonidazole and 
pimonidazole meet these criteria and bind to intracellular 
macromolecules. Several studies have indicated that 
nitroimidazole containing compounds have longer 
retention times in hypoxic cells than in normal cells. 
They have been used with immunohistochemical staining 
methods for in vivo studies. Fluorinated (19F) and 
radiolabeled 2-nitroimidazole compounds have also been 
used in 19F-MRI (as contrast agents) and nuclear medicine 
(as noninvasive imaging of hypoxia), respectively (Sun 
et al., 2011). 2-nitroimidazoles diffuses into cells and 
are reduced by intracellular reductases. In the presence 
of oxygen, they are re-oxidized and clear from cell. 
However, in the absence of oxygen, further reduction 
occurs yielding radical anions and reactive alkylating 
amine derivatives, which covalently bind to thiol groups 
of intracellular proteins and trapped in the cell ( Linder et 
al., 1994; Krohn et al., 2008; Mees et al., 2009). 
Non-invasive imaging of tumor hypoxia in 
nuclear medicine
Measuring	hypoxia	in	vivo	is	difficult.	External	imaging	
techniques such as nuclear imaging can provide 
information about tissue oxygen levels. Nuclear medicine 
utilizes radiolabeled compounds for molecular imaging 
using positron emission tomography (PET), single photon 
emission computed tomography (SPECT) or gamma 
scintigraphy. There is a great interest in nuclear medicine 
in developing imaging agents that localize in hypoxic cells, 
since hot-spot images are more sensitive than negative 
or cold-spot images. Thus 2-nitroimidazole compounds, 
which selectively retain in hypoxic cells, have been 
radiolabeled and used in nuclear medicine using PET and 
SPECT. The	 first	 successful	 radiopharmaceutical	 agent	
based on 2-nitroimidazole is 18F-Fluoromisonidazole 
(18FMISO) which provides clinical images not only from 
necrotic tumor tissues but also ischemic myocardium in 
patients and experimental animals. Although it has been 
widely used in several studies in humans and animals, it has 
not been approved for routine clinical application because 
of some limitations. Its relatively high lipophilicity 
leads	 to	 high	 nonspecific	 binding,	 long	 washout	 times,	
slow localization in hypoxic cells, and a number of 
radioactive metabolites (Mees et al., 2009). Newer 
derivatives of 2-nitroimidazole compounds have been 
developed and evaluated such as 18F-Fluoroetanidazole 
(18FETA), 18F-Fluoroerythronitroimidazole (18FETNIM), 
18F-Fluoroazomycin-arabinofuranoside (18FAZA), and 
123/124I-iodoazomycin-arabinoside (123/124IAZA). The 
new compounds are more water soluble with better 
pharmacokinetic properties (rapid clearance from blood 
and normal cells) (Mees et al., 2009). They are still in 
clinical trial stages.
A novel PET radiotracer that localizes in hypoxic 
tissue is 62Cu(II)-diacetyl-bis(N-mthylthiosemicarbazone) 
(62Cu-ATSM), a non-imidazole imaging agent which 
is composed of a metal complex of radioactive copper 
with ATSM. Cu(II)-ATSM is a neutral lipophilic small 
molecule which diffuses easily from blood into cells (rapid 
blood clearance). It is reduced in cells by cellular reducing 
equivalents and trapped in the hypoxic cells. Several 
clinical studies have approved its selective behavior for 
tumor hypoxia imaging ( Mees et al., 2009; Sun et al., 
2011). Though more clinical studies are required. 
For routine clinical SPECT imaging, 99mTc is the 
radionuclide of choice. This is because it has good 
radiation physical characteristics [IT, 140 keV (90%), 
6 h] and is available through an inexpensive 99Mo/99mTc 
generator. Furthermore, it is well developed and has 
varied chemistry (Schibli and Schubiger, 2002). 
The localization of 2-nitroimidazole in hypoxic tissues 
led to the preparation of nitroimidazoles substituted with 
the neutral, lipophilic technetium (v) oxo propyleneamine 
oxime (PnAO) complexes. 99mTc-labeled compounds, 
″BMS181321	 and	 BRU59-21″	 are	 2-nitroimidazole	
coupled to PnAO-type chelators. BMS181321,	 the	 first	
99mTc-labelled 2-nitroimidazole, and its structural isomer 
BRU59-21	were	developed	and	studied for tumor hypoxia 
imaging (Linder et al., 1994; Zhang et al., 2000). They 
have shown selective accumulation of radioactivity in 
hypoxic tissues. Although 99mTc-labelled BMS181321 
retains in hypoxic cells in vitro and localizes in animal 
tumor models, it has never been used in clinical setting 
because of its in vitro and in vivo instability, high blood 
levels and extensive hepatobiliary excretion related to the 
high	octanol/water	partition	coefficient	(P=40)	(Sun	et	al.,	
2011). 
BRU59-21	 (P=12),	 a	 second	generation	 analogue	of	
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BMS181321, has more stability in vitro and more rapid 
clearance compared to BMS181321. In preclinical studies 
it has proven to be safe and suitable for tumor hypoxia 
imaging (Mees et al., 2009; Sun et al., 2011). 
P	 value	 (octanol/water	 partition	 coefficient)	 of	
2-nitroimidazoles plays a crucial role on pharmacokinetic 
and biodistribution of these compounds. Since 
modification	of	P	in	these	compounds	was	limited,	Zhang	
et al. coupled 2-nitroimidazole to peptidic N3S chelators 
for 99mTc. In these compounds, the value of P depends to 
amino acids. 
The study demonstrated that a peptidic chelator to 
2-nitroimidazole did not prevent the nitro group from 
being reduced enzymatically (Zhang et al., 2000). Peptides 
offer advantages over antibodies or proteins such as ease 
of production, small size, better penetration into tissues, 
favorable pharmacokinetics, and fewer immunologic 
reactions (Aloj and Morelli, 2004). The importance 
of peptide radiopharmaceuticals has encouraged vast 
researchers	 to	 apply	 an	 easy,	 fast	 and	 efficient	 peptide	
radiolabeling methods. Regarding high potential of 
peptides in diagnosis and therapy, radiopeptides containing 
2-nitroimidazoles seem to be appropriate candidates for 
tumor hypoxia imaging.
Conclusion
At present, a few PET radiopharmaceuticals as hypoxia 
imaging agents are in clinical trial stages; however, 
their use is limited because they are expensive and only 
available	 at	 specific	 nuclear	medicine	 centers.	This	 has	
led to development of 99mTc-labeled compounds which 
are less expensive and more convenient to use. Since 
2-nitroimidazole compounds have shown selective 
accumulation in hypoxic cells in human and animal 
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